Neonorm.com allows online ordering and features in-depth product
information for dairy and beef farmers, foal owners and veterinarians to
help drive sales
SAN FRANCISCO--(BUSINESS WIRE)--Jun. 7, 2017--
Jaguar Animal Health, Inc. (NASDAQ: JAGX) (Jaguar), an animal health
company focused on developing and commercializing first-in-class
gastrointestinal products for companion and production animals, foals,
and high value horses, and Napo Pharmaceuticals, Inc. (Napo), a human
health company developing and commercializing novel gastrointestinal
prescription products from plants used traditionally in rainforest
areas, today announced Jaguar’s launch of neonorm.com,
a commercial website for Neonorm™ Foal and Neonorm™
Calf, Jaguar’s lead non-prescription products.
Neonorm™ Foal is a natural, clinically-tested, non-drug
product designed for use as an anti-diarrheal in newborn horses.
Diarrhea is one of the most common clinical complaints in foals,
especially within the first 30 days of life. The crippling effects of
dehydration that often result from secretory diarrhea in foals can
manifest quickly, precipitate adverse health effects and lead to death.
Neonorm™ Calf has been formulated and clinically tested to
help proactively retain fluid in dairy calves and reduce the severity of
diarrhea—aiding calves in avoiding debilitating, dangerous levels of
dehydration associated with scours.
allows online ordering of both Neonorm™ Foal and Neonorm™
Calf directly from Jaguar and features in-depth product information,
customer testimonials, and FAQs to help drive sales. The new site is a
component of the integrated, multichannel marketing initiatives Jaguar
launched during the first half of 2017 in support of Jaguar’s Neonorm™
commercial strategy of connecting directly with dairy and beef farmers,
bovine veterinarians, equine veterinarians, horse owners and other
members of the equine community in a targeted, engaging way to help
build the Neonorm™ brand and drive sales—both directly and
through Jaguar’s core dairy market distributor as well as Henry Schein,
Inc., Jaguar’s exclusive distributor for Neonorm™ Foal.
Sample customer testimonials appearing on Neonorm.com:
“My experience was very positive. Used Neonorm™ Foal on two
different thoroughbred foals and it was effective on both. Thanks!” -
Tim Tompkins, Oak Orchard Farms
“We saw Neonorm™ Foal advertised on an RFD-TV show and
talked with our vet about it. We bought it as an ‘in-case-we-need-it’,
we feel it’s very inexpensive insurance to have on hand!” - Mike and
Teresa Thompson, MT Acres, LLC
“We’ve used Neonorm™ Calf on close to 100 calves and it is
working really well.” - Chelsea Lavoie, Metcalf Farm
also features ongoing monthly “Selfie Contests” designed to drive
engagement with existing and prospective Neonorm™
Foal and Neonorm™
Calf customers. To enter the contests, registered site visitors
upload a selfie photo of themselves with a dairy or beef calf, or a
selfie photo of themselves with their foal. Contest winners are
determined based on votes cast by other registered site visitors for
Neonorm™ is a standardized botanical extract derived from the Croton
lechleri tree that acts at the same last step in a physiological
pathway generally present in mammals. Foaling season in the northern
hemisphere generally runs from May through September, while calf scours
season in the U.S. generally runs from March through June.
As announced March 31, 2017, Napo and Jaguar have entered a definitive
merger agreement. The proposed merger of Jaguar and Napo remains subject
to customary conditions to closing. Upon the consummation of the merger,
Jaguar’s name will be changed to Jaguar Health, Inc., and Napo will
operate as a wholly-owned subsidiary of Jaguar, focused on human health.
As previously stated, Jaguar and Napo expect the merger to close by the
end of July 2017.
About Napo Pharmaceuticals, Inc.
San Francisco-based Napo Pharmaceuticals, Inc. focuses on the
development and commercialization of proprietary pharmaceuticals for the
global marketplace in collaboration with local partners.
For more information, please visit www.napopharma.com.
About Jaguar Animal Health, Inc.
Jaguar Animal Health, Inc. is an animal health company focused on
developing and commercializing first-in-class gastrointestinal products
for companion and production animals, foals, and high value horses.
Canalevia™ is Jaguar’s lead prescription drug product
candidate, intended for the treatment of various forms of diarrhea in
dogs. Equilevia™ (formerly referred to as SB-300) is Jaguar’s
prescription drug product candidate for the treatment of
gastrointestinal ulcers in horses. Canalevia™ and Equilevia™
contain ingredients isolated and purified from the Croton lechleri
tree, which is sustainably harvested. Neonorm™ Calf and
Neonorm™ Foal are Jaguar’s lead non-prescription products.
Neonorm™ is a standardized botanical extract derived from the Croton
lechleri tree. Canalevia™ and Neonorm™ are
distinct products that act at the same last step in a physiological
pathway generally present in mammals. Jaguar has nine active
investigational new animal drug applications, or INADs, filed with the
FDA and intends to develop species-specific formulations of Neonorm™
in six additional target species, formulations of Equilevia™
in horses, and Canalevia™ for cats and dogs.
For more information about Jaguar, please visit www.jaguaranimalhealth.com.
Certain statements in this press release constitute “forward-looking
statements.” These include statements regarding the proposed merger
between Jaguar and Napo, the expectation that the proposed merger will
close by the end of July 2017, Jaguar’s intention to develop
species-specific formulations of Neonorm™ in additional
target species, and Jaguar’s plan to develop formulations of Canalevia™
for cats, horses and dogs. In some cases, you can identify
forward-looking statements by terms such as “may,” “will,” “should,”
“expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,”
“project,” “contemplate,” “believe,” “estimate,” “predict,” “potential”
or “continue” or the negative of these terms or other similar
expressions. The forward-looking statements in this release are only
predictions. Jaguar has based these forward-looking statements largely
on its current expectations and projections about future events. These
forward-looking statements speak only as of the date of this release and
are subject to a number of risks, uncertainties and assumptions, some of
which cannot be predicted or quantified and some of which are beyond
Jaguar’s control. Except as required by applicable law, Jaguar does not
plan to publicly update or revise any forward-looking statements
contained herein, whether as a result of any new information, future
events, changed circumstances or otherwise.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170607005723/en/
Source: Jaguar Animal Health, Inc.
Jaguar Animal Health
Peter Hodge, 203-539-0423